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Abstract  
 
          In oncology, treating cancer with a beam of photons is a well established 
therapeutic technique, developed over 100 years, and today over 50% of cancer 
patients will undergo traditional X-ray radiotherapy. However, ionizing radiation 
therapy is not the only option, as the high-energy photons delivering their cell-killing 
radiation energy into cancerous tumor can lead to significant damage to healthy 
tissues surrounding the tumor, located throughout the beam's path. Therefore, in 
nowadays, advances in ionizing radiation therapy are competitive to non-ionizing 
ones, as for example the laser light based therapy, resulting in a synergism that has 
revolutionized medicine. The use of non-invasive or minimally invasive (e.g. through 
flexible endoscopes) therapeutic procedures in the management of patients represents 
a very interesting treatment option. Moreover, as the major breakthrough in cancer 
management is the individualized patient treatment, new biophotonic techniques, e.g. 
photo-activated drug carriers, help the improvement of treatment efficacy and/or 
normal tissue toxicity. Additionally, recent studies support that laser technology 
progresses could revolutionize cancer proton therapy, by reducing the cost of the 
needed installations.  
The aim of this review is to present some laser-based future objectives for 
cancer radiation therapy, aiming to address the relevant advances in the ionizing and 
non-ionizing radiation therapy, i.e. protons and heavy ions therapy, as well as 
photodynamic targeted and molecular therapies.  
 
1. INTRODUCTION  
 
Today, one of the major health problems for mankind is cancer. Cancer is the 
second most common cause of death in the US, exceeded only by heart disease, 
accounting for nearly 1 of every 4 deaths [1]. In developed countries every year some 
40,000 per 10 million inhabitants are diagnosed as having cancer, while the World 
Health Organization has projected cancer-related mortalities to rise to over 11 million 
by 2030 [2]. Obviously, the universal demand in oncology is early cancer diagnosis 
on one part, and to remove cancer or precancerous growths or to relieve symptoms of 
cancer in the case of disease. The armamentarium of cancer treatment includes 
surgery, radiotherapy and chemotherapy. Among them, treating cancer with a high-
energy photons beam is a well established therapeutic technique, developed over 100 
years, and today is the most widely used modern cancer treatment - over 50% of 
cancer patients in developed countries will undergo traditional X-ray radiotherapy to 
cure their disease. Typically, the higher the dose, the more effective the radiotherapy 
is in destroying cancer. However, ionizing radiation therapy has also side effects, as 
the high-energy photons releasing their energy into malignant cells can also lead to 
significant damage to healthy tissues surrounding the tumor. Therefore, in nowadays, 
advances in cancer radiation therapy stare at a shift in the electromagnetic radiation 
spectrum to non-ionizing photons. For example, the laser based surgery and new 
biophotonic techniques, such as photodynamic therapy and targeted nanomedicine 
with photo-activated drug carriers, are used to improve cancer treatment efficacy 
concomitantly reducing normal tissue toxicity.  
The year 2015 it was proclaimed by the UN General Assembly and it was 
celebrated worldwide as the ―International Year of Light‖, just four years after the 
50th anniversary of the discovery of the laser radiation. During the first 50 years laser 
light period, both research developments and applications of laser radiation are 
impressive, particularly in medicine (in all areas: diagnosis, therapy, rehabilitation 
and biomedical research and technology). In oncology, there are as well several 
biophotonic applications and ongoing research efforts in both early diagnosis and 
imaging, as well as in novel treatment options. Based on the relevant realizations, 
several groups worldwide protract the idea that, after the predominance of ionizing 
radiation therapy in the 20
th
 century, the 21
st
 century raised as the Biophotonics era 
for life sciences. Is this an optimistic target for human health improvement? In an 
attempt to answer this and the rhetoric question set in the title of this work ―Cancer 
and electromagnetic radiation therapy: Quo Vadis??‖, it is useful to review first the 
basic concepts of what is cancer and what is expected in our days from cancer 
radiation therapy.  
 
What is cancer?  
 
Cancer is a group of diseases caused by normal cells changing so that they 
grow in an uncontrolled way. Cancer is characterized by this uncontrolled growth or 
cell proliferation, which causes a lump or a collection of cells called a tumor to form, 
and by the spread of abnormal cells in distant tissues (metastasis). If the tumor is not 
treated and the metastasis is not controlled, cancer can cause problems and may 
eventually lead to the patient's death. The origin of the word cancer is credited to the 
Greek physician Hippocrates (460-370 BC), who used the terms carcinos and 
carcinoma to describe non-ulcer forming and ulcer-forming tumors. Carcinos was a 
giant crab in Greek mythology and, later, the Roman physician Celsus (28-50 BC) 
translated the Greek term into cancer, the Latin word for crab, [3]. Furthermore, the 
word tumor is from the Latin verb tumere, meaning to bulge or to swell [4]. However, 
not all swellings are tumors (e.g., an inflammation or other lumps). As already 
mentioned, tumor originates from the transformation of normal cells into cancer cells 
(carcinogenesis, from the Greek words carcinos=crab and genesis=birth), which 
acquire the ability to become unresponsive to normal physiological controls. 
According to Tracqui [4], this simple statement embraces the extremely diverse and 
complex reciprocal dialogues that cells and molecules comprising a tumor engage 
through highly regulated interactions favoring malignancy. Definitely, carcinogenesis 
is a multistep process, involving genetic alterations, as for example mutations in the 
genes regulating cellular growth, inhibition of programmed cell death (apoptosis), 
activation of oncogenes and deactivation of tumor suppressor genes.  
As cancer is not just one disease but many diseases, we discriminate more than 
100 different types of cancer. Most cancers are named from the organ or type of cell 
in which they start - for example, cancer that begins in the colon is called colon 
cancer; cancer that begins in melanocytes of the skin is called melanoma. 
Furthermore, cancer types can be grouped into broader categories. Obviously, 
different types of cancer can behave very differently. Apart of the organ of tumor‘s 
origin, more generally, tumors are classified according to the embryonic origin of the 
tissue from which they derive. We know from the science of embryology that, during 
the third week of the embryonic stage, three germ cell layers develop from which all 
organs and tissues originate. The three embryonic germ layers are the endoderm, 
mesoderm, and ectoderm. The term carcinoma is used to denote cancers of 
endodermal (e.g., gut epithelia cancers) or ectodermal (e.g. from tissue of the body‘s 
surface, skin and mucosa) origin. Ectodermal tumors also include cancers occurring in 
organs derived from epithelial structures such as the gastro-intestinal tract, liver, 
pancreas, respiratory, and urogenital tract. Cancers of mesodermal origin (e.g., bones, 
muscle, blood cells, or other connective or supportive tissue) are called sarcomas. 
Leukemia (blood cell cancers) is also classed as mesodermal cancers. Carcinomas 
make up more than 90% of malignant tumors. For definitions of other cancer-related 
terms, the interested reader can see several European, e.g. [5], or American 
governmental websites, e.g. [6].  
As we mentioned, the universal effort in oncology is to remove cancer or 
precancerous growths or to assure a palliative intervention, to relieve the symptoms of 
cancer. However, even after many years of clinical research and practice, there are 
several obstacles in the effective treatment of the cancer worldwide and this disease is 
still uncontrollable. We still need to elucidate several aspects of tumor biology, tumor 
growth and its impact in cancer treatment, tumor regression etc. Definitely, the fight 
of cancer demands a multidisciplinary effort to cover the complications of the disease.   
 
2. Tumor growth and the impact in cancer treatment  
 
Tumor growth is a very complex phenomenon. Additionally to carcinogenesis, 
tumor growth occurs because of the proliferation of the tumor cells and the 
development of supporting stroma and vasculature (by angiogenesis). More 
specifically, the cumulative effect of carcinogenesis and mutagenesis is malignant 
transformation of cells, rapid growth and proliferation of these malignant cells, 
amplified angiogenesis, invasion into organs and body cavities, and subsequent 
metastasis. As we mentioned briefly before, metastasis refers to the spread of the 
cancerous cells from the point of origin to other body parts and systems through the 
vascular and lymphatic circulation systems. Although some tumors (e.g. leukemias, 
ascites tumors) grow as cell suspensions, most tumors grow as solid masses of tissue. 
Solid tumors make up more than 90% of all of human cancers [7]. Solid malignant 
tumors are basically composed of neoplastic cells, collectively called parenchyma, 
and non-tumorous elements, the stroma. The stroma and the neo-vasculature that 
arises provide tumor cells with oxygen and nutrients necessary to survive and grow 
[8]. The neo-vasculature also allows for the removal of toxic waste products 
associated with cellular metabolism [9] and is one of the two vehicles for metastatic 
spread, e.g. through the bloodstream (the other one is through the lymph system).  
The study of the tumor development and growth has several distinct features; 
the biological approach for the natural history and the evolution of a specific tumor, 
the therapeutic procedures for tumor shrinkage and necrosis, and the mathematical 
approach for these inter-related processes. As many review papers and books are 
describing the basic biological models of tumor growth, in this work we will just 
mention briefly on the mathematical models of tumor growth, based on mathematical 
simulation and expressions of the dependence of tumor size on time, and their impact 
in cancer treatment. Nowadays, it is generally accepted that mathematical models are 
an efficient way to complement the results of preclinical research and clinical trials. 
Beside animal models and cell lines, which are often used for preclinical studies, there 
are computer models (in silico models) encompassing analytical (mathematical) or 
stochastic methodology, as well as physical and engineering concepts representing the 
biological world [10].   
Since cell division is a binary process, it can be expected that tumor growth 
would be an exponential function with the volume increasing as a semi-logarithmic 
function of time. This implies a constant time for the tumor to double in volume 
(volume doubling time). Small tumors often express this form of growth function but, 
as they get larger, the growth rate of a tumor usually declines (longer doubling time) 
due to nutrient deprivation and other conditions [11, 12]. For the reader further 
interested to the biophysical models of tumor growth, a comprehensive review was 
reported by Tracqui some years ago [4].  
The fact that cancer is characterized by uncontrolled cell proliferation has 
stimulated biomathematicians to construct different cell proliferation models 
(continuous, discrete, deterministic, stochastic) describing growth and kinetics of 
abnormal cell multiplication. Late 90‘, collaborating with the Greek ―In Silico 
Oncology Group‖, led by Stamatakos, we reported our efforts to model in vitro tumor 
spheroids growth for small lung cell carcinoma and the impact of radiotherapy, with 
spatial visualization and a simplified simulation method [12, 13]. Certainly, over the 
last decades considerable efforts have been made worldwide in order to simulate 
tumor growth and the impact to various anti-cancer treatment schemes. The work on 
simulation included some of the most advanced mathematical medical science, such 
as stochastic cellular automata, discrete event simulation, hypermatrices and discrete 
operators [14]. A further step towards shaping an emerging analytical-computational 
discipline of ‗‗In Silico Radiation Oncology‘‘ performed by Stamatakos and his group 
with the elaboration of a four-dimensional, patient individualized, in vivo simulation 
model of glioblastoma multiforme tumor response to radiotherapy of [15]. Five years 
ago, the organizers of the ―4th International Advanced Research Workshop on In 
Silico Oncology and Cancer Investigation‖, hold in Athens - Greece, described in the 
scope of the workshop that: ―Cancer is a natural phenomenon and as such it should 
be amenable to mathematical and computational description. Clinically driven 
complex multiscale cancer models can produce rather realistic spatio-temporal 
simulations of concrete clinical interventions such as radio-chemotherapy applied to 
individual patients. Clinical data processing procedures and computer technologies 
play an important role in this context [16]‖. In this framework, a Euro-Japanese effort 
to develop the ―Oncosimulator‖ was funded by the European Commission (EC) 
project ―Advancing Clinico-Genomic Trials on Cancer‖ [14], while the clinical 
adaptation and validation of the multiscale modeling component of the system is in 
progress [17].  
Coming back to the natural history and the biology of a tumor, we recall that 
the growth of a tumor is controlled by oxygen and nutrient supply (for example, 
nutrients as amino acids and glucose). Solid tumors begin as avascular polyps 
dependent upon the diffusion of oxygen and nutrients across the tumor surface. 
Further growth depends on the recruitment and proliferation of blood vessels through 
angiogenesis and is fueled by metabolic resources in the host environment [18]. In 
their comprehensive theory, Herman et al [18] presented a general quantitative 
framework that captures many of the essential features of tumor vascularization and 
growth, and how these are influenced by the host organism in an allometric theory to 
tumor growth modeling. There is abundant evidence that when a tumor has grown to a 
detectable size, its central region usually contains only dead cells and, therefore this 
central region of dead cells is called necrotic core of the tumor. In figure 1, a 
schematic representation of cross-section of a multi-cellular spheroid solid tumor is 
illustrated, based on the Greenspan mathematical model to mimic the growth of 
spherical necrotic tumors [19]. In this scheme, we can distinguish a concentric 
collection of large proliferating tumor cells located in a well oxygenated area in the 
periphery, while smaller non-proliferating cells populate deeper regions. The number 
of the ―dormant‖ hypoxic tumor cells, which are far away from blood vessels than the 
normal diffusion distance of oxygen (about 100 μm to 150 μm), increase with 
spheroid size [19].   
 
 
Figure 1. Schematic representation of a multi-cellular solid tumor. Within the quasi-
spherical shape, a concentric arrangement of aerobic and proliferating tumor cells 
are located in the periphery, while a smaller fraction of non-proliferating cells are 
concentrated in deeper regions, surrounding a core of dead cells (central necrotic 
core), emerging as a result of cell death due to diffusion limitations to oxygen and 
nutrients supply.   
 
As we already mentioned, the stroma and the neo-vasculature that arises 
provide solid malignant tumors with oxygen and nutrients necessary to survive and 
grow [8]. Nevertheless, the neo-vasculature blood vessels in the tumor are very 
different from normal vasculature. They are typically highly irregular and tortuous, 
have arterio-venous shunts and blind ends, lack smooth muscle or nerves and have 
incomplete endothelial linings and basement membranes [7]. As a result, the delivery 
of oxygen and nutrients to the tumor cells is much less efficient than in normal tissues 
and, therefore, the overall levels of oxygen in most tumors are low, resulting in areas 
with extremely hypoxic cells, surrounding the core area with anoxia. These hypoxic 
cells, developed in tumors because of the unbalanced growth of the tumor cells and of 
the vascular components needed to provide them with a sufficient blood supply, are 
radiation-resistant, limiting in some instance the effectiveness of the radiotherapy of 
cancer.  
The hypoxic fractions of tumors are present in most of the human and 
experimental animal tumors, depending on tumor type, the degree of tumor 
differentiation, the tumor growth rate and the host tissue characteristics. Definitely, 
tumors contain a mixture of aerobic and hypoxic cells and this intra-tumoral 
heterogeneity is a common characteristic of solid tumors, depending on the cell type 
and on tumor microenvironment conditions. For more than sixty years ago, the tumor 
hypoxia impact to radiation therapy outcome is a headache for oncologists, as a 
possible cause for failure of local control of tumor response to radiation. Soon after 
the discovery of X-ray radiation and at the very beginning of experiments in radiation 
biology, it was reported by Schwarz in 1909 that the presence or absence of oxygen 
had a strong influence on the effectiveness of radiation to produce damage [20, cited 
in 21]. He demonstrated reduced skin toxicity when the skin was compressed (i.e. 
oxygen level reduced through expulsion of blood), although the specific role of 
oxygen was not known at that time. Moreover, the landmark papers of Gray et al. 
(1953) [22] and Thomlinson and Gray (1955) [23] pointed out the basic significance 
of the presence or absence of oxygen to the radiation response of malignant tissues 
undergoing radiotherapy. Thomlinson and Gray [23] postulated that, based on their 
histological studies on human lung adenocarcinomas, tumor cells would be forced 
away from blood vessels, beyond the effective diffusion distance of oxygen in 
respiring tissue, thereby becoming hypoxic and eventually necrotic. Furthermore, both 
experimental radiation biology research and clinical radiotherapy data, worldwide, 
show that, in the absence of oxygen, the dose of X-rays to produce the same degree of 
cell-killing as under well-oxygenated conditions would need to be increased by a 
factor of about 3 or even 5 in some tumors [24]. The increased killing of cells, 
observed in the presence of oxic conditions, is called ―oxygen effect‖ and the 
quantitative expression of this phenomenon is given by the ―oxygen enhancement 
ratio‖ (OER), defined as the ratio of doses under anoxic/hypoxic to aerobic 
conditions, to give the same cell survival or the same radiobiological effect. This is 
because oxygen molecules react rapidly with the free-radical damage produced by 
ionizing radiation in DNA, thereby ‗fixing‘, or making permanent, the DNA damage 
that leads to cell death [22]. Several investigators support that hypoxic cells are also 
resistant to most anticancer drugs, as hypoxic cells are distant from blood vessels and, 
therefore, are not adequately exposed to some types of anticancer drugs.  
Since hypoxia was recognized as an obstacle in cancer radiotherapy, several 
methods have been proposed to overcome it: a) hyperbaric oxygen therapy, b) neutron 
radiotherapy, c) hypoxic cells radiosensitization. The third approach is related to 
chemical modification of cellular radiosensitivity, by changing the mechanism of the 
overall radiolysis of the system. At this point, we have to mention another factor that 
critically influences the clinical outcome of cancer radiation treatment, specifically 
the intrinsic tumor radiosensitivity. Radiosensitivity is the probability of a cell, tissue 
or organ of suffering an effect per unit of radiation dose. There are several factors 
affecting the radiosensitivity, as for example physical factors (e.g. linear energy 
transfer, dose fractionation), chemical (e.g. oxygen, radio-protectors) and biological 
factors (e.g. cell cycle phase). According to the early observations of Bergonié and 
Tribondeau and their law stated at the beginning of the 20th century (1906), an 
increased sensitivity to radiation is observed in populations of cells that are highly 
proliferative (i.e. with rapid cell divisions) and less differentiated (i.e. stem cells are 
more sensitive than mature somatic cells). In other words, cellular radiosensitivity is 
proportional to the rate of cell proliferation and inversely proportional to the degree of 
cell differentiation. As a consequence, radiosensitivity of cells varies considerably as 
they pass through the cell cycle with, in general, late S-phase (synthesis of DNA) 
being most radio-resistant, very late G2 and mitosis most radio-sensitive and G1 
phase taking an intermediate position [11, 25]. Substantial evidence through the 
decades of clinical cancer radiotherapy suggests that the intrinsic radiosensitivity of 
the tumor cells is the primary biological determinant of tumor response to radiation 
[26].  
 
3. Current treatment strategies for cancer  
 
Cancer is treated with both invasive and non-invasive treatment modalities, 
such as surgery, radiation therapy, chemotherapy, as well as other therapeutic 
modalities (e.g. immunotherapy, hormone therapy, biological therapy, photodynamic 
therapy) and a combination of these (e.g. radiosurgery). In oncology, the desired anti-
cancer therapeutic clinical effect can be due to direct target tumor cell death by 
necrosis or apoptosis, vascular damage leading to tissue ischemia and resultant target 
cell death, or immune modulation, or a combination of these. Among the non-invasive 
treatment procedures, radiation therapy or radiotherapy is one of the most common 
treatments for cancer. Radiation therapy kills cancer cells that are dividing quickly 
and grow out of control, while it is desirable to avoid and/or minimize any damage to 
the surrounding normal cells. Traditional radiotherapy uses high energy 
electromagnetic waves, specifically photons (e.g. X-rays, gamma rays) or particles 
(e.g. electron beams, neutrons, carbon ions, alpha particles, and beta particles) to 
destroy tumor cells by damaging their DNA. Some ways that ionizing radiation can be 
given include: external beam radiation therapy, brachytherapy or internal radiation 
therapy, or use of injected radiopharmaceuticals. Radiation can be given alone or used 
in combination with other treatments, such as surgery or chemotherapy.  
Chemotherapy uses chemical compounds to kill cells that divide rapidly, one 
of the main properties of cancer cells. This means that it also harms cells that divide 
rapidly under normal circumstances, as for example cells in the bone marrow, in the 
digestive tract and in hair follicles. In addition to pure chemotherapy, certain chemical 
agents (drugs), the so called radiosensitizers, can actually enhance cell response to 
ionizing radiation and they generally promote both the direct and indirect effects of 
radiation, facilitating the radiation to better destroy cancer cells, while side effects 
towards normal tissues are minimized. During the progress of the radiotherapy epoch, 
several chemical compounds (radiosensitizers) or physical agents (hyperbaric oxygen, 
hyperthermia) were developed to enhance the radiotherapeutic effect. Since the early 
pioneers in this field (G.E. Adams, J.F. Fowler, and J. Denekamp at Gray Cancer 
Institute in Mount Vernon Hospital, UK) [27], a plethora of research studies and 
applications were and are still performed on several radio-sensitization procedures to 
improve cancer radiotherapy [28]. Among them, hyperthermia is an adjuvant cancer 
treatment modality based on the cytotoxic properties of localized high temperatures 
(43 
o
C) achieved within cancer cells and tissues. Hyperthermia is a treatment known 
from ancient times, but the renaissance of the method was mainly based on the 
modern electromagnetic heating techniques and is usually achieved by using 
microwaves to heat the tumor [14, 29].  
Returning to radiotherapy of cancer, we have to spot that contemporary 
research and development in radiation oncology is mainly directed to further increase 
the treatment rates. This is currently achieved by the application of new ionizing 
radiation treatment modalities, such as intensity modulated radiotherapy (IMRT), 
intensity modulated arc-therapy, proton and heavy ion radiotherapy [11]. For instance, 
protons are already today used in radiotherapy to cure cancer by damaging 
irreversibly the DNA of cells, while allowing for a much-reduced collateral damage to 
surrounding healthy tissues [25], especially for deep-seated tumors. Proton therapy 
demonstrates this advantage because the physics of proton therapy is fundamentally 
different from the physics of conventional photons irradiation. Definitely, it is well 
documented that the basic difference between X-ray photons and particles is their 
different biological action and different depth-dose distribution. Photons show an 
exponentially decreasing energy deposition with increasing depth in tissue. In 
contrast, as pointed out first by Wilson in 1946, protons deposit their energy near the 
end of their path, leading to a maximum (the well-known ―Bragg peak‖ phenomenon) 
near the end of range of the proton beam, without significant lateral scatter [30]. As a 
consequence, healthy tissues or adjacent critical organs located upstream and 
downstream of the tumor are practically unaffected by the irradiation. One can say 
that the curves of the distribution of the ionizing photons and the particles energy dose 
in depth behave as two mirrored curves [31]. Nevertheless, the enthusiasm for the 
medical applications of proton particles in oncology is somehow restricted by the 
uncertainties that can affect the accurate prediction of proton range in vivo [32] and by 
the high cost of proton treatment installations. Protons are accelerated conventionally 
by means of devices that use electric fields of two basic types: linear accelerators 
(linacs) and circular accelerators (e.g. cyclotron). Due to the above mentioned 
advantages of proton therapy, if ion accelerators were small and cheap as electron 
linacs, then probably radiotherapy would be made with protons, more precise and 
with the same therapeutic effects of γ-rays. However, because proton therapy is a 
costly treatment for cancer, today 99% of external beam radiotherapy is done with γ-
rays and only a few centers in the world use ―conventional‖ sources to perform 
proton-therapy, including approximately 8 centers in USA, 4 in Japan, 2 in China, 1 in 
Switzerland, 1 in Germany 1 in Korea, etc. According to ―Particle Therapy Co-
Operative Group‖, [http://ptcog.web.psi.ch/], for the year 2010, there were 31 active 
proton therapy centers, 2 heavy ion facilities, and approximately 12 neutron therapy 
centers in operation. There were as many as 22 new, planned, or proposed proton 
therapy centers, some of which today are already under construction. In some of these 
new centers it is proposed to combine both proton and heavy ion therapy facilities. 
Therefore, in nowadays all over the world, the advances in photon therapy continue to 
be competitive with the much more expensive hadrons therapy [33, 34]. Besides 
particles, high energy X-ray radiotherapy was considered as an alternative to cure 
deep-seated cancer. The treatment of pediatric tumors is one of the most important 
indications for proton therapy because a clear clinical benefit by means of reduced 
toxicity is assumed [25]. The high-energy photon beams, produced mostly by electron 
linacs, have energies of a few million electron volts, but are still called X-rays by 
medical doctors [35]. They have replaced low-energy X-rays and the gamma radiation 
from radioactive cobalt in some radiotherapy procedures because they deposit the 
dose (the energy per unit mass) at greater depth. For a qualitative representation of 
tissue simulator‘s depth dependence of the deposited dose, for different types of 
radiation, one can see the relevant figure, easily assessed on web 
(http://cds.cern.ch/record/1733872/files/vol46-issue10-p017fig.png?version=1), or in 
[35]. In the majority of the depth-dose distribution curves, liquid water target is 
usually chosen as a tissue simulator, due to the fact that biological tissues exhibit a 
large diversity and it is very difficult to correlate the published results. Nevertheless, 
significant deviations appear from water to real tissues, but water phantoms are still a 
common point of reference between radiotherapy centers worldwide. As an example, 
in Figure 2, the computer simulated depth-dose distribution (i.e. the Bragg peak 
position) is shown for a beam of protons, having initial incident energy of 200 MeV, 
in a target of liquid water, 1g/cm
3
 density. The proton stopping power calculations 
were performed with the Monte Carlo computer code SRIM and the results show that 
protons of 200 MeV incident energy are characterized by an axial ion range of 
penetration, in liquid water, of Rm=256 μm. The statistical parameters of kurtosis and 
of asymmetry (skewness) that characterize this penetration depth are -0.8723247 and 
51228 respectively.  
 
 
 
Fig. 2. Depth dependence of the deposited energy dose in water, for protons of 200 
MeV, with the narrow Bragg peak at the end. 
 
Without doubt, in anti-cancer fighting armamentarium, radiotherapy poses a 
principal position. On the other hand, radiotherapy based on ionizing radiation could 
not be the only option, as the high-energy photons releasing their energy into 
cancerous tumor can lead to significant damage to normal tissues surrounding the 
tumor. Therefore, advances in ionizing photon and particle radiation therapy 
modalities are still under investigation to enhance efficient and safe procedures. 
Simultaneously, there is a tendency to develop novel cancer treatment strategies based 
specifically on biophotonic principles, e.g. on the use of non-ionizing photons. In 
Biophotonics, the use of laser light photons, from ultraviolet to infrared part of the 
electromagnetic spectrum, gives totally new or older but revised biomedical 
applications in both diagnosis and therapy of human diseases. For example, powerful 
laser light beams are used instead of conventional scalpels for very careful and precise 
surgical work, including treating some cancers. Surgical excisions, performed with 
laser light, cause a non-contact, less bleeding (haemostasis) and damage to normal 
tissue than standard surgical tools do (mechanical or electrical scalpel), and there is a 
lower risk of infection and scarring. As another paradigm, photodynamic therapy 
(PDT) is a type of cancer treatment that uses visible or near infrared laser light to 
destroy tumors. Photodynamic therapy is a non-invasive or minimally invasive 
treatment technique, based on the simultaneous action of the following three factors, 
schematically represented in Figure 3: i) photosensitizing agents, able to 
photochemically eradicate malignant cells, ii) oxygen, generating highly reactive 
singlet oxygen, and iii) non-thermal monochromatic light irradiation. Briefly, in PDT, 
a certain drug, called photosensitizer or photosensitizing agent, is injected into a 
patient and distributed all over the patient‘s body. After a couple of days, the 
photosensitizer is preferentially accumulated in cancer cells. Laser light is then used 
to activate the agent and destroy cancer cells, in the presence of cellular oxygen [36].  
In PDT, the light is usually monochromatic light, chosen to coincide with the 
maximum absorption wavelength of the photosensitizing agent molecules, in the red 
or near infrared part of the spectrum. The ideal light wavelength must give the proper 
photonic energy needed to photo-activate molecules for excitation and singlet oxygen 
production, as well as to ensure a good penetration of light in the tissue. These 
requirements impose the use of photons in the 600 – 850 nm part of the 
electromagnetic spectrum, since at wavelengths higher than 850–900 nm the photons 
might not have sufficient energy to produce 
1
O2 and the most energetic photons in UV 
– VIS part of the spectrum have low penetration depth. The photo-generated singlet 
oxygen (
1
O2) attacks cellular targets, causing destruction through direct cellular 
damage, vascular shutdown, and activation of an immune response against targeted 
cells.  
 
 
Figure 3: In PDT, laser light activates a photosensitizing compound to destroy cancer 
cells, in the presence of cellular oxygen.  
 
We already mentioned that PDT is a non-invasive (especially in skin 
pathology) or minimally invasive (through flexible endoscopes in several internal 
organs) therapeutic procedure. Photodynamic therapy is also considered as a light-
activated chemotherapy, which achieves a localized effect due to tumor selectivity of 
the photosensitizer, in contrast of traditional chemotherapy, which has a systemic 
effect. PDT is low cost, repeatable and less painful than conventional radiotherapy 
methods, while can also be effective for situations in which surgery is contra-
indicated. Apart of PDT, laser light can be directly used to remove surgically cancer 
or precancerous tumors or to relieve symptoms of cancer, such as bleeding or 
obstruction.  
The first demonstration of the photosensitization induced by ordinary light in 
oxygen-dependent chemical reactions and the term ―photodynamic‖ were reported by 
Raab and von Tappeiner in 1904, over a century back. Nevertheless, the first attempts 
to use photosensitizing drugs for the cure of skin diseases dates back to ancient Egypt, 
India, and Greece, where psoralen-containing plant extracts and sun light 
(heliotherapy) were applied to treat psoriasis and vitiligo. On the other hand, the 
growing use of contemporary PDT is based on the pioneering work of Dougherty and 
associates [37], signalling the new PDT era. Indeed, considerable interest in 
phototherapy was regained since the discovery of the first laser by Maiman in 1960 
and by the discovery of porphyrins as potential tumor localizers by several 
researchers. After the first laser-based clinical PDT report in late 1970‘s [37], the 
number of the relevant scientific research publications, for this rapidly expanding 
field, has been increasing exponentially. The history of PDT was presented in detail in 
several papers, as for example in a comprehensive review by Moan and Peng [38].  In 
the modern PDT era, this concept is still evolving rapidly and a great effort has been 
devoted towards the development of new photosensitizing agents, which exhibit 
specific light absorption and tissue distribution properties, as well as the development 
of cost effective monochromatic light sources, emitting in the photosensitizer 
absorption wavelength.  In the last decades, PDT has begun to find approved uses in 
medicine and now is applied in oncology in many countries. However, photodynamic 
therapy has still some limitations in its clinical applicability, due to the necessity for 
accessibility to light of a deep located tumor.  
Although PDT was originally developed as a tumor therapy, some of its most 
successful applications are also for non-malignant diseases [38]. Focusing in PDT 
clinical applications in oncology, in 1996 the FDA in USA approved PDT with 
hematoporphyrin derivative (HpD) as photosensitizer drug (Photofrin™) for palliative 
treatment of obstructive esophageal cancer, while two years later the FDA approved 
PDT with Photofrin™ for treatment of certain esophageal and obstructive lung 
cancers. A variety of other applications are evolving in clinical trials, including 
treatment of prostate cancer, head & neck cancer, skin cancer, pleural cancer, 
intraperitoneal cancer, and treatment of the resection bed after brain tumor surgical 
excision [39]. For the first twenty years of PDT, a review of this rapidly expanding 
field was presented in 1998 by Dougherty et al [36], receiving thousands of citations. 
Ten years later, in 2008, Wilson and Patterson published a comprehensive review 
paper [40], summarizing the status of PDT clinical applications with an emphasis on 
the contributions of physics, biophysics and technology, and the challenges remaining 
in the optimization and adoption of this treatment modality. Consequently, novel 
biophotonic modalities for both experimental and clinical PDT applications are in 
progress, on the subject of advanced light sources, new photosenitizers and 
optimization of both drug and light dose distribution in the lesion. Apart of the first 
generation of photosensitizers, nowadays there are new drugs that have been approved 
for PDT treatments. Porfimer sodium, temoporfin, 5-aminolevulinic acid and 
verteporfin are the most commonly used photosensitizers.  
A very interesting problem, faced by several researchers and clinicians, is the 
complexity of PDT dosimetry due to the dynamic nature of the three, simultaneously 
acting, essential components—light, photosensitizer and oxygen, in order to control 
and optimize the photodynamic treatment efficacy. For example, an insufficient 
photosensitizer concentration in malignant tissue can lead to incomplete treatment of 
tumor, resulting in recurrence, while, in contrary, the photosensitizer overdose may 
cause significant damage to the healthy surroundings during the photodynamic 
treatment of the tumor [41]. Definitely, at least the first period of clinical PDT 
treatments was ruled worldwide by empirically prescribed dosimetry approaches. In 
an effort to develop a non-empirical monitoring method for PDT dosimetry, we 
measured in a preliminary work the absorption and laser induced fluorescence spectra 
in tissue phantoms, for identification and quantification of the concentration of the 
photosensitizer tetra(m-hydroxyphenyl)chlorin (m-THPC, Foscan
®
) [42]. Regarding 
the dosimetry in photodynamic therapy, apart from the drug dose (e.g. the 
photosensitizer concentration in tumor), the light distribution in malignant tissue is 
also very important, which is governed by both the laser beam properties (e.g. 
wavelength, beam geometry, continuous wave or pulsed irradiation) and the optical 
parameters of the tissue (e.g. absorption coefficient, scattering coefficient, scattering 
anisotropy factor, and fluorescence quantum yield). The interdependence of these 
parameters and their implications for developing adequate dosimetry for PDT was 
examined in late 90‘s by Wilson et al. [43]. They termed as ―explicit dosimetry‖ the 
traditional dosimetry approach, in which each dose factor (the administered 
photosensitizer dose, the incident light dose and the drug-irradiation time interval) is 
measured independently, versus to ―implicit dosimetry‖, where the photosensitizer 
photobleaching is measured as an index of the effective delivered dose [43]. As we 
already mentioned, irrelevant to different photoactivated compounds used, many 
factors, such as oxygenation and vasculature, are influencing the cytotoxic outcome of 
PDT. Briefly, any oxygenation modification during PDT, resulting in oxygenation 
deficiency (i.e. hypoxia) or in photobleaching, as well as any chemical or physical 
factor that could modify the hemodynamics of the tissue may alter the photodynamic 
efficacy of PDT. More than a decade ago, we tried experimentally to follow the 
protective effect of ocreotide, a compound analog to somatostatin, supposing that 
ocreotide may have a modulating effect on tetra(m-hydroxyphenyl)chlorin (m-THPC, 
Foscan
®
) mediated photodynamic action in normal pig stomach, by decreasing the 
splachnic blood flow and/or suppressing the inflammatory process in the peptic 
system [41]. In modern PDT era, several methods are reported for the monitoring of 
the impact of photobleaching and hemodynamic responses to photodynamic therapy 
of cancer, targeting the effective dosimetry of PDT [44, 45].   
Recently, in a mini review, we presented the outlines of the basic 
photophysical mechanisms that operate in PDT on a molecular and cellular level, as 
well as some of the new approaches in cancer therapy, concerning either the 
combination of PDT with radiotherapy, or the advances in drug delivery and the 
monitoring of the relevant photo-induced damage [46]. Definitely, many strategies 
have been proposed to maximize and potentiate the therapeutic effects of 
photodynamic therapy when used in combination with other curative modalities [47]. 
In this review, the authors report several applications of combined therapy in which 
PDT, being the core therapeutic partner, has been associated with both traditional and 
innovative therapeutic approaches for cancer treatment [47].  
Regarding the cancer cells damage mechanism(s), it is noteworthy to spot the 
following paradoxical phenomenon: novel therapeutic strategies are developed to 
preferentially kill cancer cells through reactive oxygen species (ROS), although, in 
the same time, ROS are generally involved in cancer initiation (carcinogenesis), 
progression and metastasis. In nowadays, there are several research studies and 
therapeutical applications that answer this contradictory subject, addressed 
rhetorically by Wang and Yi as ‗‗cancer cell killing via ROS – to increase or decrease, 
that is the question‘‘ [48]. Therefore, the research efforts for optimization of cancer 
therapeutic strategies worldwide include the use of ROS-mediated cancer cells 
damage in photodynamic therapy, in combination with targeted drug delivery to 
secure selectivity. Moreover, as the major breakthrough in cancer management is the 
individualized patient treatment, new biophotonic techniques, e.g. photo-activated 
drug carriers, help the improvement of treatment efficacy and the obliteration of the 
normal tissue toxicity. For example, bioconjugated nanoparticles behave as Trojan 
horse for the delivery and targeting of anti-cancer drugs, taking advantage of 
increased ROS in cancer cells to enhance therapeutic activity and selectivity [46]. The 
use of non-systemic drug administration to the target, in conjunction with non-
invasive or minimally invasive biophotonic therapeutic procedures (through flexible 
endoscopes), represents a very interesting personalized treatment option for patients. 
Indeed, any endoscope can be fitted with optical fibers or waveguides that transmit 
coherent (laser) or incoherent light and that light could precisely aim to cut surgically 
or destroy photo-dynamically a tumor.  
In addition to PDT, recent studies support the possibility of photodynamic 
therapy and conventional radiotherapy combination. Concerning this combination, it 
is well known that the principal target for ionizing radiation-induced cell killing is 
nuclear DNA. Ionizing radiation causes DNA damage of cancerous cells by the 
generation of reactive oxygen species (ROS), especially DNA double strand breaks. 
Since PDT also induces several types of DNA lesions through singlet oxygen 
generation, there is a potential for synergism in cell killing due to interactions 
between the two modalities [49]. Moreover, radiosensitization of hypoxic tumor cells 
in combination with photosensitization of well oxygenated malignant tissue could 
eventually be a new alternative for optimization of cancer therapy [28]. This 
trimodality therapy, including drugs, ionizing radiation and visible light (in the 
electromagnetic spectrum wavelength range of 400 – 800 nm) results in additive or 
even synergistic effects on some lines of carcinoma cells [50]. However, although the 
double role of some chemical compounds as both a photo- and radio-sensitising 
agents promises unique perspectives for a concerted action of the two modalities to 
achieve a better control of tumor growth, the clinical outcome is not very well 
researched.  
The last decades, with the rapid development of the nanotechnology, 
alternative methods have also been studied using nanosystems and nanomaterials for 
cancer treatment. Gold and ceramic nanoparticles, quantum dots, nanotubes, 
liposomes and dendrimers have been examined as drug delivery systems in 
personalized nanomedicine and the relevant pharmaceutical technology [46]. Ten 
years ago, Sinha et al. [50] reviewed the use of bioconjugated nanoparticles for the 
delivery and targeting of anticancer drugs. Then, they considered that the on-going 
efforts of scientists, researchers, and medical personnel and the future perspectives of 
nanotherapeutics in cancer, including the recent advances in proteomics and 
genomics, could sincerely ensure to ‗‗do big things using the very small‘‘ [50]. 
Without a doubt, nanotechnology, a flourishing scientific field that is everywhere and 
in everyday life, revolutionizes also cancer therapy by using nanoparticles as drug 
delivery systems for ROS generation.  
Alongside to pure biophotonic procedures, briefly reviewed in [46], we 
anticipate the epitome of a multidisciplinary and transnational speculation in the last 
years, which suggests that lasers could also ameliorate the well established cancer 
proton therapy, offering a novel proton acceleration modality. With this step, the 
scientists exploit the use of photons from the entire electromagnetic radiation 
spectrum, from the ionizing part to the non-ionizing one, as a novelty for cancer 
therapy.  
 
4. Bridging ionizing and non-ionizing radiation to cancer therapy  
 
As we already mentioned, proton therapy needs a high cost, very sophisticated 
technology requiring expensive facilities and, therefore, the relevant treatment units 
are still a few decades around the world. Almost 100,000 patients have been 
successfully treated with hadrons (protons and carbon ions) worldwide (PTCOG 
2014, http://www.ptcog.ch/). Sophisticated proton therapy, based on conventional 
accelerators such as cyclotrons or synchrotrons, is now, and is likely to continue to be, 
more expensive than sophisticated  (i.e., intensity-modulated) X-ray therapy, and the 
ratio of costs of proton vs. X-ray therapy per treatment fraction was estimated to be 
about 2.4 at 2005 [51]. State-of-the-art techniques borrowed from particle accelerators 
and detectors are increasingly being used in the medical field for the early diagnosis 
and treatment of tumors and other diseases. Novel technologies are under 
development, being expected to decrease the size and cost of proton therapy units and 
to increase the potential availability of proton therapy. Forty years after the discovery 
of laser light, the unique properties of the intense laser radiation brought new ideas in 
the acceleration of high-energy ion beams and a solid bridge between the ionizing and 
non-ionizing areas of electromagnetic radiation applications was established, as it is 
artistically illustrated in Figure 4. The interconnection of the possibilities of using an 
extended part of the electromagnetic spectrum in the biomedical applications field is 
definitely very attractive for novel, efficient and safer treatment strategies. At the 
beginning of 21
st
 century, one century after the development of X-ray cancer radiation 
therapy, some laser-based future objectives for cancer radiotherapy were reported 
with great expectations. Their special properties make lasers versatile tools for 
biomedical applications that include very sophisticated anti-cancer therapeutical 
modalities. For example, as there was much expectation placed upon hadrons therapy, 
laser-driven proton acceleration was proposed to offer a potentially more compact 
(based on ―table-top‖ laser systems) and significantly cheaper and convenient 
approach to generate a beam of protons for radiotherapy [52].  
 
 
 
Figure 4. Artistic visualization of a bridge between the ionizing and non-ionizing 
pillars of electromagnetic waves for cancer therapy. 
 
The conversion of high-energy radiation rays into visible light photons is a 
well studied and established field (i.e. photomultiplier tubes, scintillation detectors). 
On the other hand, the concept of conversion of optical photons to charged particles is 
a very innovative expectation, based on the unique properties of laser radiation and 
the distinct laser-matter interaction mechanisms. In several laboratories all over the 
world, the research in the area of laser-driven particles acceleration has grown 
dramatically since the first experimental evidence of multi-mega-electron-volt proton 
acceleration from laser-irradiated foils, and the number of related publications in the 
scientific literature grown-up exponentially [53]. Specifically, in 2005, a multinational 
team of researchers published a comprehensive review on the main experimental 
results and the relevant theoretical and computational models, regarding the fast ion 
generation by high-intensity laser irradiation of solid targets and their applications 
[54]. One year later, examples of the research efforts results from an ongoing research 
campaign on laser-driven proton acceleration at the Lund Laser Centre (LLC) in 
Sweden were reported [54], highlighting the main mechanisms leading to ion 
acceleration in the interaction of high-intensity laser pulses with thin foil targets and 
the influence of the temporal contrast of the laser pulse on ions acceleration.  
Taking a glance at laser-driven proton therapy (LPT) basic technology, we 
present briefly the procedure: Proton acceleration is achieved by focusing a high-
power, pulsed laser on a thin foil target. The ultra short (sub-picosecond) laser pulses 
causes massive ionization and plasma creation in the target, expelling a large number 
of relativistic electrons. The sudden loss of electrons gives the target a high positive 
charge and this transient positive field accelerates protons to high energies [54]. A 
very common schematic representation of the LPT concept is illustrated in Figure 5.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic representation of laser-driven proton acceleration for cancer 
therapy. 
 
As the researchers worldwide made a progress in the elucidation of the 
mechanism(s) for intense laser radiation and matter interaction, it was possible to 
produce high currents of protons with energies spanning the spectrum from few 
hundreds of electron volts up to several tens of MeV. Apart of the general idea for 
LPT, based on the laser induced massive ionization and plasma creation in the target, 
there are two particular mechanisms for proton acceleration with laser irradiation on a 
foil: Target Normal Sheath Acceleration (TNSA) and Radiation Pressure Acceleration 
(RPA) [55-58 and the literature cited in these papers]. In TNSA, protons are 
accelerated by the electric field created by the hot electrons heated by the laser. 
However, in most cases of TNSA with thick targets, the resulting ion energy spectrum 
is broad and only few protons reach the maximum energy, which is less suitable for 
applications requiring monoenergetic protons [59]. According to [59], it seems that 
RPA is a more efficient acceleration process for producing high energy quasi-
monoenergetic protons, suitable for many applications, among them medical 
applications.    
Nevertheless, the laser challenges for plasma physics and several 
interdisciplinary areas were addressed first to fast ignition research efforts, while 
further expansion of this field was envisaged to include also medical applications. The 
progression in laser matter interaction and a state of the art review regarding the high 
energy, solid-state Petawatt lasers (Petawatt, 1 PW = 10
15
 W) for fast ignition 
research was reported in 2006 [60]. When laser pulses of such immense power are 
focused onto beam pot as small as a few μm2 only, light intensities in the order of 1020 
or 10
21
 W/cm
2
 can be achieved even in a university laboratory. During the first 21
st
 
century decade, a number of new laser systems were under construction or were 
planned to develop around the world, which would facilitate the laser-driven hadrons 
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acceleration experiments. From the already developed high-energy Petawatt lasers in 
large laser facilities, we expect that the new generation of high power lasers will 
increase the accelerated hadrons energy by orders of magnitude, culminating in the 
pan-European Extreme Light Infrastructure (ELI) project for ultrafast laser beamlines 
facilities, in which an Exawatt laser is expected to reach 10
26
 W/cm
2
 in a few years 
[61]. At intensities of this order charged particles traversing a laser wavelength gain 
huge electromagnetic energies such that even protons become relativistic. The goal of 
the new ―Extreme Light Infrastructure –ELI‖ European facilities is to yield the 
highest peak power and laser focused intensity and the expectation for the regime 
beyond the exawatt, towards the zettawatt is the next high intensity frontier [62].   
The acceleration of ions by laser irradiation of foils has been pursued actively 
using experiments, theory and numerical simulations. The experimental 
implementation of laser-driven particles acceleration has been performed by several 
research teams, in multi-national laser facilities, under very specific physical 
conditions and using pulsed laser systems with different characteristics (e.g. 
wavelength, ultrafast pulses, and light intensity).   
The majority of the recently reported studies support that lasers could 
ameliorate cancer proton therapy [61, 62]. It is reported that laser-driven proton 
acceleration offers a significantly cheaper and relatively convenient approach to 
generate a beam of protons and radiobiological experiments in this direction indicate 
that protons in laser proton therapy (LPT) kill cancer cells as effectively as those from 
accelerators. Recently, monolayers of human cervical cancer cells (HeLa) were 
exposed to laser-driven quasi-monoenergetic protons, generated with a table-top laser 
system, delivering single shot doses up to 7Gy to living cells [63]. Although the 
biophysical studies for laser-driven ion acceleration are still in their infancy, very 
promising radiobiological processes are reported, since protons and photons have a 
parallel destructive effect on the DNA of the targeted tumor cells [63].  
Recently, the global progress toward laser-driven radiotherapy is 
comprehensively reviewed in [61]. In this paper, the authors address the question if 
and how the radiobiological effectiveness (RBE) generated by laser-driven particle 
acceleration differs from that provided by conventional accelerators [61]. They 
present briefly some protons therapy centers, in operation and planned, based mainly 
in multidisciplinary transnational collaboration efforts that explore the development 
of laser-driven acceleration technology and the potential biomedical applications. 
Nevertheless, they conclude that before answering on the effectiveness of laser-driven 
hadrons therapy, we have to wait at least six years for completion of the first 
randomized trial that is testing the efficacy of conventional accelerator driven proton 
therapy and also an estimated time frames of more than 3–10 years for implementing 
laser driven ion beam radiotherapy [61].  
 
Concluding remarks  
 
In nowadays, the anti-cancer edifice has four main pillars: surgery, 
radiotherapy, chemotherapy and immunotherapy. Surgery and radiotherapy are 
considered as localized forms of treatment, while chemotherapy and immunotherapy 
are systemic treatment forms that may be used alone or in combination with other 
therapeutic modalities. As the long-standing dream in the field of cancer therapy is the 
ability to precisely treat deep-seated tumors noninvasively, it is imperative to find 
new diagnosis and therapy platforms driving this idea.  
In this review, we came across at the challenges that a broad band of 
electromagnetic radiation offers to cancer fighting methodologies. As we mentioned, 
ionizing radiation therapy of cancer is mainly considered as a local treatment 
modality, since the radiation energy is targeting well-defined areas of the body, where 
there is the tumor volume. Nevertheless, there is a risk of unwanted irradiation of 
healthy tissue surrounding a targeted tumor that may cause secondary carcinogenesis 
or may promote invasion and migration of cancer cells, leading to metastasis. 
Moreover, not all the forms of radiation therapy can reach safely and effectively all 
parts of the body, especially if cancerous cells have spread to distant areas. Therefore, 
a new approach causing selectivity to malignant cells and no damage to tissue 
surrounding tumors is needed. At this point, the revolution in the fields of 
monochromatic and coherent laser light physics and technology gave to the oncology 
stage new diagnosis, therapy and monitoring modalities. The use of laser scalpel for 
cancer surgery and new biophotonics treatment techniques, such as photodynamic 
therapy and photo-activated drug carriers were introduced in oncology to improve 
cancer treatment efficacy and concomitantly to reduce normal tissue toxicity. 
Definitely, PDT is an emerging cancer-treatment modality. Moreover, the possibility 
that laser could not only fire directly at the malignant tissue, but can also be used to 
irradiate thin foil targets for laser-driven particle acceleration gives notable 
perspectives in cancer therapy. According to Ledingham et al. [61], the overall 
challenge for laser-driven ion beam radiotherapy is ―to develop well-controlled, 
reliable energetic ion beams of very high quality that can meet stringent medical 
requirements with respect to physical parameters and performance‖, representing a 
viable alternative in the 21
th
 century‘ radiotherapy.  
Facing cancer in one site and the impact of the novelties in the electromagnetic 
radiation therapy field in the other site, we must take in consideration that the 
majority of the involved research teams are primarily trained in physics, chemistry, 
mathematics, pharmacology, nanotechnology and engineering and that, eventually, 
they require an interfacing bridge between technology and clinics to integrate their 
scientific advances in clinical use. On the other hand, clinicians classically are not 
predisposed to attempt into advanced technology research, suspending the 
implementation of sophisticated technology improvements for a ―bench-to-bedside‖ 
approach. The history of clinical and experimental cancer radiotherapy reflects this 
interconnection of basic science and meaningful health outcomes in medical practice. 
Moreover, the latest progress of nanotechnology signed new perspectives in oncology 
and new diagnostic and therapy platforms, driving the expansion of personalized 
medicine.  
The basic idea of personalized or targeted cancer therapy is to deliver the precise 
dose of a drug to the individual patient, at the right time interval, according to his 
tissue-response endpoints. Therefore, the scope of personalized medicine is broad and 
aims to encompass the complex biology intrinsic to most cancers. Hopefully, the 
possibility of data handling and processing, by using high performance computing and 
informatics, ensures the draw-on of novel cancer monitoring treatment modalities, 
despite the plethora and the heterogeneity of data on cancer biology processes. In this 
aspect, in combination with the emergent scientific, technological and medical 
discipline of in silico oncology, computational cancer models are expected to enhance 
individualized treatment optimization, through experimentation in silico, i.e. on the 
computer [16]. Without doubt, as a major breakthrough in cancer management is the 
individualized patient treatment, the new biophotonic techniques, e.g. photo-activated 
drug carriers, could definitely help the improvement of treatment efficacy and/or the 
elimination of normal tissue toxicity. For example, considering the experimental 
achievements of optical trapping and manipulation of cells, we can extend the 
possibilities of firing certain regions within a cell, which is successfully manipulated 
by optical forces, using a sophisticated laser micro-scalpel method, to irradiate a 
specific cell or region of a cell, instead of the entire cell population of a tumor.  
In conclusion, trying to predict what does the future hold for cancer therapy, it 
seems that the gold era of cancer radiation therapy in 21
st
 century will be marked by 
the exploitation of the entire spectrum of electromagnetic waves, in order to expand 
the interface between imaging and therapy and to devise effective treatment strategies 
for all types and stages of cancer, in benefit of humanity.  
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